UCB to create 330 jobs with AI-powered biologics manufacturing facility

UCB announced that it has selected Gwinnett County, Georgia as the location for its new U.S. biologics manufacturing facility. The campus will be state-of-the art, using a digital-first approach by leveraging AI, robotics, and automation while being natural resources efficient. The project represents a major milestone in UCB's previously announced U.S. expansion and reinforces the company's long-term commitment to patients, innovation, and sustainable growth in one of its fastest-growing markets.

Spanning approximately 460,000 square feet or roughly the size of eight football fields, the state-of-the-art campus will sit on 79 acres and is designed to be a cornerstone of UCB's global biologics manufacturing network. Once operational, the facility is expected to produce complex Biologics 24/7 primarily for the U.S. market. In combination with UCB's global network, the facility will strengthen UCB Supply resilience globally while the new campus will serve as a hub for our U.S. Manufacturing Operations, underscoring our long-term commitment to the U.S.

The new facility will:

• Strengthen UCB's global biologics manufacturing network
• Enhance supply chain resilience
• Support growing demand for its biologics portfolio and future pipeline

"When we met with UCB leadership earlier this year in Belgium, we discussed how the Peach State would be the right partner for their visionary plans in the U.S. that will benefit both patients and hardworking Georgians," said Governor Brian Kemp. "UCB's announcement is also a significant milestone for our life sciences industry, representing one of the largest investments in state history and establishing both the Rowen facility and Georgia as a true hub of innovation in this field."

Economic Impact and Job Creation

The significant investment is expected to generate approximately $5 billion in total economic impact, including:

• Around 330 permanent highly skilled jobs
• More than 1000 construction jobs

"As we execute on our strategy of growth, this manufacturing site will support the commercial production of recently approved and future pipeline medicines, bringing them closer to patients and representing the full depth of our patient value chain, from research, to development, to commercial, and manufacturing operations in the U.S.," said Taco van Tiel, Head of UCB in the U.S. "UCB currently employs around 2,000 people in the U.S., who are striving every day to reach as many people that can benefit from our innovative medications as possible, and this new campus further contributes to elevating the lives of the patients and caregivers we serve."